Articles

Results from the CHRYSALIS study show that amivantamab demonstrates robust and durable antitumor activity and a manageable safety profile in patients with EGFR exon20ins-mutated non–small-cell lung cancer. Read More ›

A substantial minority of patients with advanced non–small-cell lung cancer and highly actionable gene variants were not prescribed available targeted therapies in the Veterans Health Affairs National Precision Oncology Program. Read More ›

Approximately 30% of patients with non–small-cell lung cancer present with early-stage (I-IIIA) disease and undergo surgery. Researchers assessed the use of adjuvant osimertinib in this population. Read More ›

The frequency and durability of outcomes associated with acquired resistance to PD-1 inhibition in non–small-cell lung cancer are presented. Read More ›

The characteristics of long-term responders to PD-1 blockade are presented. Read More ›

For oncologists and others who advocate for smoking cessation, it is important to know whether recent quitters who are diagnosed with lung cancer can achieve a survival benefit. Read More ›

Weekly epirubicin was evaluated as a potential “gentle” option for second-line chemotherapy in patients with malignant pleural mesothelioma after failure of first-line pemetrexed-based chemotherapy. Read More ›

Combining nivolumab plus ipilimumab with 2 cycles of chemotherapy may be effective in patients undergoing first-line treatment for metastatic non–small-cell lung cancer. Read More ›

Developing novel targeted therapies for patients with cancer who have rare mutations, such as PI3K/AKT/mTOR pathway alterations, is particularly challenging for researchers. Read More ›

Patients with platinum-pretreated small-cell lung cancer may benefit from combination use of cediranib, an oral VEGF inhibitor, and olaparib, a PARP inhibitor. Read More ›